Industry
Biotechnology
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, and eicosapentaenoic acid. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.
Loading...
Open
0.47
Mkt cap
187M
Volume
1.5M
High
0.48
P/E Ratio
-4.55
52-wk high
1.37
Low
0.45
Div yield
N/A
52-wk low
0.45
Portfolio Pulse from
November 19, 2024 | 3:45 pm
Portfolio Pulse from Benzinga Newsdesk
October 30, 2024 | 8:13 pm
Portfolio Pulse from Benzinga Newsdesk
August 22, 2024 | 12:33 pm
Portfolio Pulse from Benzinga Newsdesk
July 31, 2024 | 6:28 pm
Portfolio Pulse from Benzinga Newsdesk
July 31, 2024 | 11:06 am
Portfolio Pulse from Benzinga Newsdesk
July 31, 2024 | 11:02 am
Portfolio Pulse from Benzinga Newsdesk
July 29, 2024 | 10:50 am
Portfolio Pulse from Benzinga Newsdesk
July 17, 2024 | 8:18 pm
Portfolio Pulse from Benzinga Newsdesk
July 17, 2024 | 8:18 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.